FTC Approves $2.2B Hikma Deal, Pending Divestitures
The U.S. Federal Trade Commission signed off on Hikma Pharmaceuticals PLC's $2.2 billion purchase of Boehringer's U.S. generics business Thursday, after the U.K. drugmaker agreed to divest certain assets to quell...To view the full article, register now.
Already a subscriber? Click here to view full article